Financial Results for the quarter ended on June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eyantra Ventures reported standalone revenue of ₹1,422.11 lakhs for Q1 FY26, up sharply from ₹495.38 lakhs in Q1 FY25 (about 187% growth), driven mainly by sale of merchandise and IT services. However, standalone profit after tax fell steeply to ₹5.58 lakhs from ₹81.19 lakhs a year ago, as expenses scaled faster than revenue. On a consolidated basis, revenue jumped to ₹1,956.41 lakhs but the company swung to a net loss of ₹342.62 lakhs, largely because the newly consolidated subsidiary Neuro and Spine Associates contributed a loss of about ₹336.54 lakhs. The statutory auditor (PRSV & Co. LLP) issued an unqualified review report with no qualifications or emphasis of matter. The board also approved a new Employee Stock Option Scheme (ESOP 2025), appointed a new Secretarial Auditor, and set the 40th AGM for September 30, 2025.
Strong top-line growth is being offset by sharply weaker profitability — both standalone and consolidated PAT have turned flat or negative, signalling heavy margin compression and integration costs from the newly acquired hospital/pharmacy subsidiary. Shareholders should monitor whether revenue growth can be translated into profits going forward, as the stock may face pressure until margins recover.